目的 研究环糊精包合对大鼠肠道菌群体外降解转化丹参酮ⅡA的影响。方法 将丹参酮ⅡA及其β-环糊精包合物分别与离体大鼠肠道菌群孵育液共同培养0、6、12、18、24 h 后取样,经HPLC测定丹参酮ⅡA含量。结果 大鼠肠道菌群对丹参酮ⅡA具有显著的降解作用,形成包合物后,丹参酮ⅡA的降解速率变慢。在降解18 h后,丹参酮ⅡA原料药组及其β-环糊精混合物组中药物下降比例分别为(74.23±2.32)%、(84.98±1.14)%,包合物组中丹参酮ⅡA的下降比例为(47.45±4.01)%。结论 在离体条件下,大鼠肠道菌群可以在24 h 内将丹参酮ⅡA基本降解完全,而环糊精包合可以减缓丹参酮ⅡA被肠道菌群降解的速率。
Abstract
OBJECTIVE To observe effects of β-cyclodextrin inclusion on tanshinone ⅡA in the degradation which in rat intestinal flora in vitro. METHODS Culturing the tanshinone ⅡA and inclusion compound separately with incubation buffer of rat intestinal flora, sampling after 0、6、12、18、24 h. Extracting the sample then analyze content by HPLC. RESULTS The tanshinone ⅡA is degraded obviously by rat intestinal flora in vitro and degradation speed became slower after forming the inclusion compound. After degrading 18 h, the declining proportion of tanshinone ⅡA concerntration which in tanshinone ⅡA group and mixture of tanshinone ⅡA with β-cyclodextrin group reached (74.23±2.32)% and (80.23±1.14)% while (47.45±4.01)% in β-cyclodextrin inclusion group. CONCLUSION The tanshinone ⅡA is degraded almost completely by rat intestinal flora in vitro during 24 h, the degradation speed will be slower while forming the inclusion compound.
关键词
丹参酮ⅡA /
β-环糊精 /
包合物 /
肠道菌群
{{custom_keyword}} /
Key words
tanshinone ⅡA /
β-cyclodextrin /
inclusion compound /
intestinal flora
{{custom_keyword}} /
中图分类号：
R944
R965
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] CHEN F Y, GUO R, ZHANG B K. Advances in cardiovascular effects of tanshinone ⅡA[J]. Chin Pharm J(中国药学杂志), 2015, 50(9):1649-1653.
[2] YAN J, FENG J, YANG X, et al. Recent progress on pharmacological effects and therapeutic use of tanshinone ⅡA[J]. Pract Pharm Clin Remed(实用药物与临床), 2015,18(8):972-977.
[3] ZHANG Y, SU H P, WEN L, et al. Preparation of PLGA-hydroxypropyl-β-cyclodextrin-tanshinone ⅡA polymer nanosystems[J]. Guangdong Chem Ind(广东化工), 2016,43(3):18-21.
[4] XIAO J, WANG Y, WANG X H, et al. Advances in the intestinal bacteria metabolic of chemical compositions from Chinese medicine[J]. Chin J Exp Tradit Med Form(中国实验方剂学杂志), 2012, 18(5):247-251.
[5] YANG X W. Absorption, Distribution, Metabolism and Excretion of Chinese Herbal Medicine(中药成分的吸收、分布、代谢、排泄毒性与药效)[M]. Beijing: China Medical Science and Technology Press, 2006:183-185.
[6] YANG B, FAN Z, ZHOU L, et al. In vitro metabolic transformation of syringin by rat intestinal flora[J]. Chin Tradit Herb Drugs(中草药), 2015, 46(9):1333-1337.
[7] XIONG W N, HUANG M Q, LIANG J Q, et al. In vitro metabolism of naringin by human intestinal microflora [J].Chin J Exp Tradit Med Form(中国实验方剂学杂志), 2015, 21(12):69-71.
[8] LUDWIG A I, PENA M P, CID C, et al. Catabolism of coffee chlorogenic acids by human colonic microbiota[J]. Bio Factors, 2013, 39(6):623-632.
[9] Ch.P(2015)VolⅡ(中国药典2015 年版. 二部)[S]. 2015:1214-1215.
[10] CUI F D, LONG X Y. Pharmaceutics(药剂学)[M]. Beijing: People's Medical Publishing House (PMPH),2015:67.
[11] ZHUO M, YAN Z H, ZHANG J H, et al. Review of safety assessment for cyclodextrin and its derivatives in drug administration[J]. Elec J Translat Med(转化医学电子杂志), 2017, 4(6):77-83.
[12] ZHAO Z X, WANG Z L, ZHANG J, et al. The pharmaceutical applications of cyclodextrins[J]. Prog Mod Biomed(现代生物医学进展), 16(19):3788-3792.
[13] WANG L. Study on absorption mechanism of lipophilic components of Danshen and the method of enhance absorption [D]. Chengdu: Sichuan University, 2006.
[14] HAO H P, WANG G J, CUI N, et al. Pharmacokinetics, absorption and tissue distribution of tanshinoneⅡA solid[J]. Planta Med, 2006, 72(14):1311-1317.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(1501 KB)
